Not Yet RecruitingNot Applicable

Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps

Austria20 participantsStarted 2025-10-01

Plain-language summary

In this study, we will investigate the effect of tezepelumab on the epithelial barrier function of the upper and lower airways in patients suffering from severe asthma with and without chronic rhinosinusitis with nasal polyps. This will be achieved by analysis of epithelial barrier function upon challenge with various harmful substances (e.g. cigarette smoke extract, allergens) in cultured primary respiratory tract epithelial cells. Furthermore we will assess changes in clinical parameters, cellular composition and inflammatory mediators.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Provision of informed consent prior to any study specific procedures
✓. Age 18-99 years and willing to participate in the study
✓. Have a recorded clinical diagnosis of asthma (ICD-10 Code: J45)
✓. Undergo severe asthma treatment according to GINA/DAL treatment step 4 or 5
✓. Meet the requirements for treatment of severe asthma with Tezepelumab defined as:
✓. mucus score of ≥ 1
✓. Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 3 half-lives or 3 months have passed (whichever is longer)

What they're measuring

Change in cell index

Timeframe: 6 months

Trial details

NCT IDNCT07046117

SponsorMedical University of Vienna

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-01-31

Contact for this trial

Julia Eckl-Dorna, MD, PhD

+43140400 julia.eckl-dorna@meduniwien.ac.at

View on ClinicalTrials.gov More Asthma Bronchiale trials